InvestorsHub Logo
Followers 839
Posts 120486
Boards Moderated 18
Alias Born 09/05/2002

Re: biotech_researcher post# 651

Monday, 10/20/2014 6:39:50 PM

Monday, October 20, 2014 6:39:50 PM

Post# of 3205
Sell-on-approval is a possibility, I suppose, but it depends on the label. For instance, if ABBV/ENTA get a 12-week label for treatment-experienced cirrhotics, they will own that subgroup inasmuch as GILD's Harvoni label calls for 24 weeks of treatment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News